Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





DRG Unveils Innovative Traumatic Brain Injury (TBI) Test Panel

By LabMedica International staff writers
Posted on 04 Feb 2025

DRG Instruments (Marburg, Germany is unveiling its fully automated CLIA tests for evaluating suspected Traumatic Brain Injury (TBI) - the GFAP and UCH-L1 combo Tests – at Medlab Middle East 2025. More...

TBI can be mild or severe and is defined as damage to the brain resulting from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile. Imaging tests such as an MRI or CT scan can be performed, but these cannot detect all TBIs. This is of particular concern for those TBIs categorized as mild. Patients with mild TBI may suffer acute brain injury termed diffuse axonal injury (DAI), also known as “shearing injury,” which is not visible on standard CT and MRI scans. DAI is defined as “diffuse damage to axons in the cerebral hemispheres, in the corpus callosum, in the brainstem, and sometimes also in the cerebellum resulting from a head injury.” Brain injury biomarkers such as GFAP and UCH-L1 have effectively shown to help health care providers in providing immediate standard of care to evaluate and treat patients.

GFAP is released when astrocytes are damaged, making it a specific marker for astroglial injury, which occurs in moderate to severe TBI. Blood levels of GFAP increase soon after injury and remain elevated longer than UCH-L1, providing a longer window for detection. UCH-L1 is released into the bloodstream following neuronal injury, making it a reliable marker for neuronal damage in TBI. Elevated levels of UCH-L1 in the blood can be detected within hours after an injury, helping doctors diagnose mild to moderate TBI and differentiate it from non-brain injuries. The GFAP and UCH-L1 combo tests are designed for use on DRG's automated CLIA platform, DxDATA, enabling the measurement of GFAP and UCH-L1 blood levels within 30 minutes when patients' serum samples are collected within 12 hours of suspected traumatic brain injury. By providing fast and accurate TBI assessments, these tests increase the likelihood of immediate and effective treatment while reducing the need for radiation-based diagnostic imaging for suspected TBI.

"We are excited to bring these innovative TBI solutions to the global market," said Joerg Schloesser, Managing Director and VP of Commercial. "By leveraging automated testing and rapid turnaround times, we can help healthcare professionals make quicker, more informed decisions. Our mission is to advance patient care for those affected by traumatic brain injuries worldwide."


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.